Recent advances in targeted drug delivery systems for multiple myeloma

Ashruti Pant; Aayushi Laliwala; Sarah A. Holstein; Aaron M. Mohs

doi:10.1016/j.jconrel.2024.10.003

Recent advances in targeted drug delivery systems for multiple myeloma

Ashruti Pant, Aayushi Laliwala, Sarah A. Holstein, Aaron M. Mohs

Research output: Contribution to journal › Review article › peer-review

Abstract

Despite significant therapeutic advances, multiple myeloma (MM) remains a challenging, incurable, hematological malignancy. The efficacy of traditional chemotherapy and currently available anti-MM agents is in part limited by their adverse effects, which restrict their therapeutic potential. Nanotherapeutics is an emerging field of cancer therapy that can overcome the biological and chemical barriers of existing anticancer drugs. This review presents an overview of recent advancements in nanoparticle- and immunotherapy-based drug delivery systems for MM treatment. It further delves into the targeting strategies, mechanism of controlled drug release, and challenges associated with the development of drug delivery systems for the treatment of MM.

Original language	English (US)
Pages (from-to)	215-230
Number of pages	16
Journal	Journal of Controlled Release
Volume	376
DOIs	https://doi.org/10.1016/j.jconrel.2024.10.003
State	Published - Dec 2024

Keywords

Antibody drug conjugates
Multiple myeloma
Nanoparticles
Targeted drug delivery system

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1016/j.jconrel.2024.10.003

Cite this

@article{c8f28e4635fe43d0b60739e97421a500,

title = "Recent advances in targeted drug delivery systems for multiple myeloma",

abstract = "Despite significant therapeutic advances, multiple myeloma (MM) remains a challenging, incurable, hematological malignancy. The efficacy of traditional chemotherapy and currently available anti-MM agents is in part limited by their adverse effects, which restrict their therapeutic potential. Nanotherapeutics is an emerging field of cancer therapy that can overcome the biological and chemical barriers of existing anticancer drugs. This review presents an overview of recent advancements in nanoparticle- and immunotherapy-based drug delivery systems for MM treatment. It further delves into the targeting strategies, mechanism of controlled drug release, and challenges associated with the development of drug delivery systems for the treatment of MM.",

keywords = "Antibody drug conjugates, Multiple myeloma, Nanoparticles, Targeted drug delivery system",

author = "Ashruti Pant and Aayushi Laliwala and Holstein, {Sarah A.} and Mohs, {Aaron M.}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier B.V.",

year = "2024",

month = dec,

doi = "10.1016/j.jconrel.2024.10.003",

language = "English (US)",

volume = "376",

pages = "215--230",

journal = "Journal of Controlled Release",

issn = "0168-3659",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Recent advances in targeted drug delivery systems for multiple myeloma

AU - Pant, Ashruti

AU - Laliwala, Aayushi

AU - Holstein, Sarah A.

AU - Mohs, Aaron M.

PY - 2024/12

Y1 - 2024/12

N2 - Despite significant therapeutic advances, multiple myeloma (MM) remains a challenging, incurable, hematological malignancy. The efficacy of traditional chemotherapy and currently available anti-MM agents is in part limited by their adverse effects, which restrict their therapeutic potential. Nanotherapeutics is an emerging field of cancer therapy that can overcome the biological and chemical barriers of existing anticancer drugs. This review presents an overview of recent advancements in nanoparticle- and immunotherapy-based drug delivery systems for MM treatment. It further delves into the targeting strategies, mechanism of controlled drug release, and challenges associated with the development of drug delivery systems for the treatment of MM.

AB - Despite significant therapeutic advances, multiple myeloma (MM) remains a challenging, incurable, hematological malignancy. The efficacy of traditional chemotherapy and currently available anti-MM agents is in part limited by their adverse effects, which restrict their therapeutic potential. Nanotherapeutics is an emerging field of cancer therapy that can overcome the biological and chemical barriers of existing anticancer drugs. This review presents an overview of recent advancements in nanoparticle- and immunotherapy-based drug delivery systems for MM treatment. It further delves into the targeting strategies, mechanism of controlled drug release, and challenges associated with the development of drug delivery systems for the treatment of MM.

KW - Antibody drug conjugates

KW - Multiple myeloma

KW - Nanoparticles

KW - Targeted drug delivery system

UR - http://www.scopus.com/inward/record.url?scp=85206101213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85206101213&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2024.10.003

DO - 10.1016/j.jconrel.2024.10.003

M3 - Review article

C2 - 39384153

AN - SCOPUS:85206101213

SN - 0168-3659

VL - 376

SP - 215

EP - 230

JO - Journal of Controlled Release

JF - Journal of Controlled Release

ER -

Recent advances in targeted drug delivery systems for multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this